157 related articles for article (PubMed ID: 35869144)
1. Non-canonical EphA2 activation underpins PTEN-mediated metastatic migration and poor clinical outcome in prostate cancer.
Sachdeva A; Hart CA; Kim K; Tawadros T; Oliveira P; Shanks J; Brown M; Clarke N
Br J Cancer; 2022 Oct; 127(7):1254-1262. PubMed ID: 35869144
[TBL] [Abstract][Full Text] [Related]
2. Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells.
Tawadros T; Brown MD; Hart CA; Clarke NW
Br J Cancer; 2012 Nov; 107(10):1737-44. PubMed ID: 23037715
[TBL] [Abstract][Full Text] [Related]
3. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.
Miao H; Li DQ; Mukherjee A; Guo H; Petty A; Cutter J; Basilion JP; Sedor J; Wu J; Danielpour D; Sloan AE; Cohen ML; Wang B
Cancer Cell; 2009 Jul; 16(1):9-20. PubMed ID: 19573808
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
Mitra D; Bhattacharyya S; Alam N; Sen S; Mitra S; Mandal S; Vignesh S; Majumder B; Murmu N
Breast Cancer Res Treat; 2020 Jan; 179(2):359-370. PubMed ID: 31686261
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.
Barquilla A; Lamberto I; Noberini R; Heynen-Genel S; Brill LM; Pasquale EB
Mol Biol Cell; 2016 Sep; 27(17):2757-70. PubMed ID: 27385333
[TBL] [Abstract][Full Text] [Related]
6. EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
Garcia-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Herrero-Martín D; Huertas-Martinez J; Lagares-Tena L; Alba-Pavón P; Hontecillas-Prieto L; Mora J; de Álava E; Rello-Varona S; Giangrande PH; Tirado OM
Int J Cancer; 2018 Sep; 143(5):1188-1201. PubMed ID: 29582409
[TBL] [Abstract][Full Text] [Related]
7. EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells.
Taddei ML; Parri M; Angelucci A; Bianchini F; Marconi C; Giannoni E; Raugei G; Bologna M; Calorini L; Chiarugi P
Mol Cancer Res; 2011 Feb; 9(2):149-60. PubMed ID: 21205836
[TBL] [Abstract][Full Text] [Related]
8. Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin.
Shang X; Lin X; Howell SB
Cell Commun Signal; 2014 Oct; 12():59. PubMed ID: 25344320
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation.
Hamaoka Y; Negishi M; Katoh H
Biochem Biophys Res Commun; 2018 May; 499(4):920-926. PubMed ID: 29626472
[TBL] [Abstract][Full Text] [Related]
10. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma.
Zhang C; Smalley I; Emmons MF; Sharma R; Izumi V; Messina J; Koomen JM; Pasquale EB; Forsyth PA; Smalley KSM
J Invest Dermatol; 2021 Apr; 141(4):840-851.e4. PubMed ID: 32890629
[TBL] [Abstract][Full Text] [Related]
11. Invasion in follicular thyroid cancer cell lines is mediated by EphA2 and pAkt.
O'Malley Y; Lal G; Howe JR; Weigel RJ; Komorowski RA; Shilyansky J; Sugg SL
Surgery; 2012 Dec; 152(6):1218-24. PubMed ID: 23158188
[TBL] [Abstract][Full Text] [Related]
12. LncRNA PlncRNA-1 accelerates the progression of prostate cancer by regulating PTEN/Akt axis.
Cui Z; Gao H; Yan N; Dai Y; Wang H; Wang M; Wang J; Zhang D; Sun P; Qi T; Wang Q; Kang W; Jin X
Aging (Albany NY); 2021 Apr; 13(8):12113-12128. PubMed ID: 33848262
[TBL] [Abstract][Full Text] [Related]
13. S897 phosphorylation of EphA2 is indispensable for EphA2-dependent nasopharyngeal carcinoma cell invasion, metastasis and stem properties.
Li JY; Xiao T; Yi HM; Yi H; Feng J; Zhu JF; Huang W; Lu SS; Zhou YH; Li XH; Xiao ZQ
Cancer Lett; 2019 Mar; 444():162-174. PubMed ID: 30583071
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase C phosphorylates the EphA2 receptor on serine 892 in the regulatory linker connecting the kinase and SAM domains.
Gehring MP; Pasquale EB
Cell Signal; 2020 Sep; 73():109668. PubMed ID: 32413552
[TBL] [Abstract][Full Text] [Related]
15. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.
Taddei ML; Parri M; Angelucci A; Onnis B; Bianchini F; Giannoni E; Raugei G; Calorini L; Rucci N; Teti A; Bologna M; Chiarugi P
Am J Pathol; 2009 Apr; 174(4):1492-503. PubMed ID: 19264906
[TBL] [Abstract][Full Text] [Related]
16. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
[TBL] [Abstract][Full Text] [Related]
17. Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer.
Brown M; Roulson JA; Hart CA; Tawadros T; Clarke NW
Br J Cancer; 2014 Apr; 110(8):2099-108. PubMed ID: 24595005
[TBL] [Abstract][Full Text] [Related]
18. Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2.
Zhou Y; Yamada N; Tanaka T; Hori T; Yokoyama S; Hayakawa Y; Yano S; Fukuoka J; Koizumi K; Saiki I; Sakurai H
Nat Commun; 2015 Jul; 6():7679. PubMed ID: 26158630
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer.
Nip H; Dar AA; Saini S; Colden M; Varahram S; Chowdhary H; Yamamura S; Mitsui Y; Tanaka Y; Kato T; Hashimoto Y; Shiina M; Kulkarni P; Dasgupta P; Imai-Sumida M; Tabatabai ZL; Greene K; Deng G; Dahiya R; Majid S
Oncotarget; 2016 Oct; 7(42):68371-68384. PubMed ID: 27634912
[TBL] [Abstract][Full Text] [Related]
20. EphA2-mediated mesenchymal-amoeboid transition induced by endothelial progenitor cells enhances metastatic spread due to cancer-associated fibroblasts.
Giannoni E; Taddei ML; Parri M; Bianchini F; Santosuosso M; Grifantini R; Fibbi G; Mazzanti B; Calorini L; Chiarugi P
J Mol Med (Berl); 2013 Jan; 91(1):103-15. PubMed ID: 22903544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
